freethiadine / HEC Pharm - LARVOL DELTA

A Commentary on 'Safety, Pharmacokinetics and Antiviral Efficacy of Capsid Assembly Modulator Freethiadine in Healthy Volunteers and Chronic Hepatitis B Patients'. (PubMed, Liver Int) - No abstract available

Journal • PK/PD data • Hepatitis B • Infectious Disease • Inflammation

Safety, Pharmacokinetics and Antiviral Efficacy of Capsid Assembly Modulator Freethiadine in Healthy Volunteers and Chronic Hepatitis B Patients. (PubMed, Liver Int) - P1 | "Freethiadine has an acceptable safety profile and favourable antiviral activity in patients with CHB. These results support further investigations of freethiadine for the treatment of chronic HBV infection."

Clinical • Journal • PK/PD data • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Safety, pharmacokinetics and antiviral efficacy of freethiadine, a novel capsid assembly modulator, in healthy volunteers and patients with chronic hepatitis B virus infection (EASL-ILC 2023) - "Part 2 was a double-blind, double-dummy, randomized, entecavir controlled, multi-dose escalation study in CHB patients. Freethiadine showed an acceptable safety profile and efficacious antiviral activity in CHB patients, 200 mg freethiadine (QD or BID) can be considered for further development in treating HBV infection."

Clinical • Late-breaking abstract • PK/PD data • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Evaluation Freethiadine Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study (clinicaltrials.gov) - P1 | N=128 | Completed | Sponsor: Sunshine Lake Pharma Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Jul 2023 ➔ Jan 2023 | Trial primary completion date: Jul 2023 ➔ Jan 2023

Trial completion • Trial completion date • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Evaluation Freethiadine Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study (clinicaltrials.gov) - P1 | N=128 | Recruiting | Sponsor: Sunshine Lake Pharma Co., Ltd.

New P1 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation